Summary
11 patients with rheumatoid arthritis were treated with intravenous immunoglobulin (IVGG). In 6 patients clinical results were impressive, although lasting responses could be achieved in 3 patients only. This treatment was immunomodulating, since the immunoregulatory T-cell ratio (CD4/CD8) decreased following therapy by reducing CD4-positive cells in-vivo. By use of anti-μ-antibodies as a B-cell specific mitogen, IVGG-treatment was seen to suppress early processes of B cell activation. In parallel to these cellular effects, IVGG led to a reduction in the levels of polyethyleneglycol-precipitated circulating immune complexes as measured by lasernephelometry.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- IVGG:
-
Intravenous Immunoglobulin
- ITP:
-
Idiopathic Thrombocytopenic purpura
- RA:
-
Rheumatoid Arthritis
- ARA:
-
American Rheumatism Association
- AI:
-
Activity-Index
- CIC:
-
Circulating Immune complexes
- TCU:
-
Tetanus complex-Units
- PBMC:
-
Peripheral Blood mononuclear cells
- SI:
-
Stimulation-Index
- PWM:
-
Pokeweed mitogen
- IG:
-
Immunoglobulin
References
Becker H, Loers E, Helmke K, Federlin K (1986a) Therapie rheumatischer Erkrankungen mit Inosiplex. Immun Infekt 3:93–99
Becker H, Schauer U, Helmke K (1986b) B lymphocyte activation by insoluble anti-μ antibodies in patients with systemic lupus erythematosus. Clin exp Immunol 66:365–372
Combe B, Cosso B, Clot J, Bonneau M, Sany J (1985) Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 78:920–928
Decker JL, Malone DG, Haraoui B, Wahl SM, Schrieber L, Klippel JH, Steinberg AG, Wilder RL (1984) Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Int Med 101:810–824
Delfraissy JF, Tchernia G, Laurian Y, Wallon C, Galanaud P, Dormont J (1985) Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Brit J Haematol 60:315–322
Durandy A, Fischer A, Griscelli C (1981) Dysfunctions of pokeweed mitogen-stimulated T and B lymphocyte responses induced by gammaglobulin therapy. J Clin Invest 67:867–877
Emmerich B, Hiller E, Woitinas F, Maubach PA, Riess H, Nerl C, Geursen RG (1987) Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin. Klin Wochenschr 65:369–372
Fateh-Moghadam A, Wick M, Besinger U, Geursen RG (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet I:848–849
Hashimoto F, Sakiyama Y, Matsumoto S (1986) The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin exp Immunol 65:409–415
Helmke K, Sodomann CP, Teuber J, Federlin K (1978) Nachweis zirkulierender Immunkomplexe mit der Laser-Nephelometrie. Immun Infekt 6:173–179
Hiller E, Holler E, Geursen RG, Riess H (1986) Successful treatment with high-dose intravenous immunoglobulin in a patient with spontaneous inhibitor to factor VIII. Blut 52:123–126
Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, Baumgartner C, Morell A, Schöni M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet I:1228–1231
Janossy G, Duke O, Poulter LW, Panayi G, Bofill M, Goldstein G (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet II, 839–842
Kehrl JH, Muraguchi A, Butler JL, Falkoff RJM, Fauci AS (1984) Human B cell activation, proliferation and differentiation. Immunological Rev 78:75–96
Kimberly RP, Salmon JE, Bussel JB, Kuntz-Crow M, Hilgartner MW (1984) Modulation of mononuclear phagocyte function by intravenous γ-globulin. J Immunol 132:745–750
Leung DYM, Burns JC, Newburger JW, Geha RS (1987) Reversal of lymphocyte activation in vitro in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 79:468–472
Lin RY, Racis SP (1986) In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration. Int Archs Allergy appl Immun 79:286–290
Newland AC, Treleaven JG (1983) High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet I:84–87
Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA (1958) 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull rheum dis 9:175–176
Stiehm ER, Ashida E, Kwang SK, Winston DJ, Haas A, Gale RP (1987) Intravenous immunoglobulins as therapeutic agents. Ann Intern Med 107:367–382
Stohl W (1985) Modulation of the immune response by immunoglobulin for intravenous use. I. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin exp Immunol 62:200–207
Stohl W (1986) Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 136:4407–4413
Tsubakio T, Kurata Y, Katagiri S, Kanakura Y, Tamaki T, Kuyama J, Kanayama Y, Yonezawa T, Tarui S (1983) Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose γ-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin exp Immunol 53:697–702
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Becker, H., Mitropoulou, G. & Helmke, K. Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. Klin Wochenschr 67, 286–290 (1989). https://doi.org/10.1007/BF01892896
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01892896